Bone Biologics Corporatio... (BBLG)
| Bid | 0.97 |
| Market Cap | 2.39M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.46 |
| PE Ratio (ttm) | -0.66 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.99 |
| Volume | 80,714 |
| Avg. Volume (20D) | 159,805 |
| Open | 0.96 |
| Previous Close | 0.99 |
| Day's Range | 0.96 - 0.99 |
| 52-Week Range | 0.80 - 4.74 |
| Beta | undefined |
About BBLG
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L...
Analyst Forecast
According to 1 analyst ratings, the average rating for BBLG stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
5 months ago · businesswire.com
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross ProceedsBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
10 months ago · businesswire.com
Bone Biologics Announces Closing of $2.0 Million Public OfferingBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
10 months ago · businesswire.com
Bone Biologics Announces Pricing of $2.0 Million Public OfferingBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
